MMC vs URGN · P/E 22, rev $26.98B vs rev $109.8M
Marsh & McLennan Companies Inc (MMC) versus UroGen Pharma Ltd (URGN) — a side-by-side from cached financials, not a winner call.
Marsh & McLennan Companies Inc (MMC) is a insurance brokers company listed on US.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
Latest reported MMC revenue for 2025-12-31 was $26.98B. Net income was $4.16B. Revenue was up 10.3% from 2024-12-31 to 2025-12-31. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
Latest reported URGN revenue for 2025-12-31 was $109.8M. Net income was -$153.5M. URGN currently screens at market cap $1.61B.
MMC currently screens at market cap $89.82B and trailing P/E 21.9. URGN currently screens at market cap $1.61B.
Not investment advice. Open the MMC and URGN stock pages for the full models.
Not investment advice.